A carregar...
Emerging Opportunities for Serotypes of Botulinum Neurotoxins
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with ab...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3509704/ https://ncbi.nlm.nih.gov/pubmed/23202312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins4111196 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|